Adrian Adams's most recent trade in Akebia Therapeutics Inc. was a trade of 53,600 Stock Option (Right to buy) done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 53,600 | 53,600 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 35,700 | 200,500 (0%) | 0% | 0 | Common Stock | |
| Talphera Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Talphera Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 13,342 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,000 | 164,800 (0%) | 0% | 0 | Common Stock | |
| Acelrx Pharmaceuticals Inc | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 3,487 | 3,487 | - | - | Stock Option (Right to Buy) | |
| Acelrx Pharmaceuticals Inc | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 581 | 11,168 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 30,000 | 134,800 (0%) | 0% | 0 | Common Stock | |
| Impel Pharmaceuticals Inc | Adrian Adams | Director, COB, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 13,700 | 104,800 (0%) | 0% | 0 | Common Stock | |
| Impel Pharmaceuticals Inc | Adrian Adams | Director, COB, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | Adrian Adams | Director, COB, CEO and President | Purchase of securities on an exchange or from another person at price $ 13.81 per share. | 18 Aug 2021 | 17,203 | 17,203 | - | 13.8 | 237,506 | Common Stock |
| Impel Pharmaceuticals Inc | Adrian Adams | Director, COB, CEO and President | Purchase of securities on an exchange or from another person at price $ 14.91 per share. | 18 Aug 2021 | 2,197 | 19,400 | - | 14.9 | 32,751 | Common Stock |
| Impel Pharmaceuticals Inc | Adrian Adams | Director, COB, CEO and President | Purchase of securities on an exchange or from another person at price $ 15.89 per share. | 18 Aug 2021 | 600 | 20,000 | - | 15.9 | 9,532 | Common Stock |
| Impel Pharmaceuticals Inc | Adrian Adams | Director, COB, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Acelrx Pharmaceuticals Inc | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Acelrx Pharmaceuticals Inc | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 10,000 | 196,250 (0%) | 0% | 0 | Common Stock | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Adrian Adams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 13,700 | 91,100 (0%) | 0% | 0 | Common Stock |